The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 16540633.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Activation of the phosphoinositide 3-kinase (PI3K)/Akt cell survival pathway in many cancers makes it an appealing target for therapeutic development. However, because this pathway also has an important role in the survival of normal cells, tactics to achieve cancer selectivity may prove important. We recently showed that the cancer-selective proapoptotic protein Par-4 is a key target for inactivation by PI3K/Akt signaling. Additionally, we found that Par-4 participates in mediating apoptosis by PTEN, the tumor suppressor responsible for blocking PI3K/Akt signaling. As a central player in cancer cell survival, Par-4 may provide a useful focus for the development of cancer-selective therapeutics.
Medical subject headings
- Apoptosis Regulatory Proteins
- Neoplasms
- Phosphatidylinositol 3-Kinases
- Proto-Oncogene Proteins c-akt